Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.
2.

Challenges and opportunities in drug development for nonalcoholic steatohepatitis.

Ocker M.

Eur J Pharmacol. 2020 Mar 5;870:172913. doi: 10.1016/j.ejphar.2020.172913. Epub 2020 Jan 10. Review.

PMID:
31926994
3.

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.

Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M.

Cancers (Basel). 2019 Dec 10;11(12). pii: E1987. doi: 10.3390/cancers11121987.

4.

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications.

Klieser E, Mayr C, Kiesslich T, Wissniowski T, Fazio PD, Neureiter D, Ocker M.

Int J Mol Sci. 2019 Oct 23;20(21). pii: E5266. doi: 10.3390/ijms20215266. Review.

5.

Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2.

Irungbam K, Churin Y, Matono T, Weglage J, Ocker M, Glebe D, Hardt M, Koeppel A, Roderfeld M, Roeb E.

Lab Invest. 2020 Mar;100(3):454-465. doi: 10.1038/s41374-019-0327-5. Epub 2019 Sep 30.

6.

Epigenetic Regulation of p21cip1/waf1 in Human Cancer.

Ocker M, Bitar SA, Monteiro AC, Gali-Muhtasib H, Schneider-Stock R.

Cancers (Basel). 2019 Sep 11;11(9). pii: E1343. doi: 10.3390/cancers11091343. Review.

7.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
8.

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.

Neureiter D, Stintzing S, Kiesslich T, Ocker M.

World J Gastroenterol. 2019 Jul 7;25(25):3136-3150. doi: 10.3748/wjg.v25.i25.3136. Review.

9.

You BETer be aware - learnings from a negative Phase 1 study.

Postei-Vinoy S, Ocker M.

Oncotarget. 2019 May 7;10(34):3145-3146. doi: 10.18632/oncotarget.26898. eCollection 2019 May 7. No abstract available.

10.

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

Postel-Vinay S, Herbschleb K, Massard C, Woodcock V, Soria JC, Walter AO, Ewerton F, Poelman M, Benson N, Ocker M, Wilkinson G, Middleton M.

Eur J Cancer. 2019 Mar;109:103-110. doi: 10.1016/j.ejca.2018.12.020. Epub 2019 Jan 31.

PMID:
30711772
11.

Biomarkers for hepatocellular carcinoma: What's new on the horizon?

Ocker M.

World J Gastroenterol. 2018 Sep 21;24(35):3974-3979. doi: 10.3748/wjg.v24.i35.3974.

12.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.

13.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

14.

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F.

Br J Haematol. 2017 Sep;178(6):936-948. doi: 10.1111/bjh.14803. Epub 2017 Jun 27.

PMID:
28653353
15.

Biliary tract cancer stem cells - translational options and challenges.

Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T.

World J Gastroenterol. 2017 Apr 14;23(14):2470-2482. doi: 10.3748/wjg.v23.i14.2470. Review.

16.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

17.

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D.

Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27. No abstract available.

PMID:
28004600
18.

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):289-296. doi: 10.1097/MEG.0000000000000789.

PMID:
27906753
19.

Fibromyalgia syndrome: metabolic and autophagic processes in intermittent cold stress mice.

Oezel L, Then H, Jung AL, Jabari S, Bonaterra GA, Wissniowski TT, Önel SF, Ocker M, Thieme K, Kinscherf R, Di Fazio P.

Pharmacol Res Perspect. 2016 Sep 27;4(5):e00248. eCollection 2016 Oct. Erratum in: Pharmacol Res Perspect. 2016 Nov 24;4(6):e00277.

20.

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, Paik S, Kim HR, Cho BC.

Oncogenesis. 2016 Jul 18;5(7):e241. doi: 10.1038/oncsis.2016.48.

21.

Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid.

Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

J Clin Gastroenterol. 2017 Mar;51(3):268-277. doi: 10.1097/MCG.0000000000000581.

PMID:
27380461
22.

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.

Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M, Slater EP, Bartsch DK, Illig R, Neureiter D, Wissniowski TT.

Oncotarget. 2016 May 17;7(20):28998-9010. doi: 10.18632/oncotarget.8585.

23.

Morphological Alterations in Gastrocnemius and Soleus Muscles in Male and Female Mice in a Fibromyalgia Model.

Bonaterra GA, Then H, Oezel L, Schwarzbach H, Ocker M, Thieme K, Di Fazio P, Kinscherf R.

PLoS One. 2016 Mar 17;11(3):e0151116. doi: 10.1371/journal.pone.0151116. eCollection 2016.

24.

Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.

Montalbano R, Honrath B, Wissniowski TT, Elxnat M, Roth S, Ocker M, Quint K, Churin Y, Roederfeld M, Schroeder D, Glebe D, Roeb E, Di Fazio P.

Oncotarget. 2016 Apr 12;7(15):20312-23. doi: 10.18632/oncotarget.7950.

25.

Erratum to: DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.

Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Fränk M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R.

Apoptosis. 2016 May;21(5):671-4. doi: 10.1007/s10495-016-1224-7. No abstract available.

PMID:
26960313
26.

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.

Gelato KA, Shaikhibrahim Z, Ocker M, Haendler B.

Expert Opin Ther Targets. 2016 Jul;20(7):783-99. doi: 10.1517/14728222.2016.1134490. Epub 2016 Jan 22. Review.

PMID:
26799480
27.

In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.

Maschauer S, Gahr S, Gandesiri M, Tripal P, Schneider-Stock R, Kuwert T, Ocker M, Prante O.

Nucl Med Biol. 2016 Jan;43(1):27-34. doi: 10.1016/j.nucmedbio.2015.10.003. Epub 2015 Oct 20.

PMID:
26702784
28.

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M, Kiesslich T.

Oncotarget. 2016 Jan 5;7(1):745-58. doi: 10.18632/oncotarget.6378.

29.

Jet printing of convex and concave polymer micro-lenses.

Blattmann M, Ocker M, Zappe H, Seifert A.

Opt Express. 2015 Sep 21;23(19):24525-36. doi: 10.1364/OE.23.024525.

PMID:
26406656
30.

3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.

Mayr C, Wagner A, Stoecklinger A, Jakab M, Illig R, Berr F, Pichler M, Di Fazio P, Ocker M, Neureiter D, Kiesslich T.

Anticancer Res. 2015 Sep;35(9):4697-705.

PMID:
26254359
31.

The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.

Gahr S, Mayr C, Kiesslich T, Illig R, Neureiter D, Alinger B, Ganslmayer M, Wissniowski T, Fazio PD, Montalbano R, Ficker JH, Ocker M, Quint K.

Int J Oncol. 2015 Sep;47(3):963-70. doi: 10.3892/ijo.2015.3087. Epub 2015 Jul 16.

PMID:
26202945
32.

Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.

Kolodziej M, Goetz C, Di Fazio P, Montalbano R, Ocker M, Strik H, Quint K.

Oncol Rep. 2015 Sep;34(3):1549-56. doi: 10.3892/or.2015.4105. Epub 2015 Jul 3.

PMID:
26151768
33.

Correction: pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, Zahner D, Ocker M, Gerlich W, Glebe D, Roeb E.

PLoS One. 2015 May 1;10(5):e0127375. doi: 10.1371/journal.pone.0127375. eCollection 2015. No abstract available.

34.

Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.

Hauff P, Gottwald U, Ocker M.

Expert Opin Investig Drugs. 2015 Mar;24(3):309-27. doi: 10.1517/13543784.2015.997874. Epub 2014 Dec 30. Review.

PMID:
25547844
35.

Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE.

J Surg Res. 2015 Apr;194(2):388-93. doi: 10.1016/j.jss.2014.10.052. Epub 2014 Nov 5.

PMID:
25439321
36.

Implantable impedance plethysmography.

Theodor M, Ruh D, Ocker M, Spether D, Förster K, Heilmann C, Beyersdorf F, Manoli Y, Zappe H, Seifert A.

Sensors (Basel). 2014 Aug 13;14(8):14858-72. doi: 10.3390/s140814858.

37.

Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.

Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, Alinger B, Pichler M, Di Fazio P, Ocker M, Berr F, Neureiter D.

Mol Cell Biochem. 2014 Nov;396(1-2):257-68. doi: 10.1007/s11010-014-2161-9. Epub 2014 Jul 27.

PMID:
25064451
38.

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

Neureiter D, Jäger T, Ocker M, Kiesslich T.

World J Gastroenterol. 2014 Jun 28;20(24):7830-48. doi: 10.3748/wjg.v20.i24.7830. Review.

39.

The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas.

Quint K, Stiel N, Neureiter D, Schlicker HU, Nimsky C, Ocker M, Strik H, Kolodziej MA.

Tumour Biol. 2014 Sep;35(9):8979-89. doi: 10.1007/s13277-014-2172-x. Epub 2014 Jun 6.

PMID:
24903384
40.

Gallotannin is a DNA damaging compound that induces senescence independently of p53 and p21 in human colon cancer cells.

Al-Halabi R, Abou Merhi R, Chakilam S, El-Baba C, Hamade E, Di Fazio P, Ocker M, Schneider-Stock R, Gali-Muhtasib H.

Mol Carcinog. 2015 Oct;54(10):1037-50. doi: 10.1002/mc.22172. Epub 2014 May 6. Erratum in: Mol Carcinog. 2017 Nov;56(11):2538.

PMID:
24798519
41.

Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, Zahner D, Ocker M, Gerlich W, Glebe D, Roeb E.

PLoS One. 2014 Mar 4;9(3):e90608. doi: 10.1371/journal.pone.0090608. eCollection 2014. Erratum in: PLoS One. 2015;10(5):e0127375.

42.

The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.

Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P.

Mol Carcinog. 2015 Aug;54(8):585-97. doi: 10.1002/mc.22122. Epub 2013 Dec 23.

PMID:
24375802
43.

[Diagnosis of and therapy for hepatocellular carcinoma].

Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ.

Z Gastroenterol. 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. German.

44.

Heat dissipation after nonanatomical lung resection using a laser is mainly due to emission to the environment: an experimental ex vivo study.

Kirschbaum A, Ocker M, Bartsch DK, Quint K.

Lasers Med Sci. 2014 May;29(3):1037-42. doi: 10.1007/s10103-013-1460-9. Epub 2013 Oct 22.

45.

Embryonic transcription factors CDX2 and Oct4 are overexpressed in neuroendocrine tumors of the ileum: a pilot study.

Heverhagen AE, Geis C, Fendrich V, Ramaswamy A, Montalbano R, Di Fazio P, Bartsch DK, Ocker M, Quint K.

Eur Surg Res. 2013;51(1-2):14-20. doi: 10.1159/000353612. Epub 2013 Jul 23.

PMID:
23887079
46.

Rhenium complexes with visible-light-induced anticancer activity.

Kastl A, Dieckmann S, Wähler K, Völker T, Kastl L, Merkel AL, Vultur A, Shannan B, Harms K, Ocker M, Parak WJ, Herlyn M, Meggers E.

ChemMedChem. 2013 Jun;8(6):924-7. doi: 10.1002/cmdc.201300060. Epub 2013 Apr 8.

47.

Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.

Montalbano R, Waldegger P, Quint K, Jabari S, Neureiter D, Illig R, Ocker M, Di Fazio P.

Transl Oncol. 2013 Apr;6(2):143-57. Epub 2013 Apr 1.

48.

The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models.

DI Fazio P, Montalbano R, Quint K, Alinger B, Kemmerling R, Kiesslich T, Ocker M, Neureiter D.

Oncol Lett. 2013 Jan;5(1):127-134. Epub 2012 Oct 1.

49.

Epidermal growth factor-induced modulation of cytokeratin expression levels influences the morphological phenotype of head and neck squamous cell carcinoma cells.

Makarova G, Bette M, Schmidt A, Jacob R, Cai C, Rodepeter F, Betz T, Sitterberg J, Bakowsky U, Moll R, Neff A, Sesterhenn A, Teymoortash A, Ocker M, Werner JA, Mandic R.

Cell Tissue Res. 2013 Jan;351(1):59-72. doi: 10.1007/s00441-012-1500-y. Epub 2012 Nov 1.

PMID:
23111772
50.

GBP-1 acts as a tumor suppressor in colorectal cancer cells.

Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, Vieth M, Waldner M, Steinberg P, Hohenadl C, Stürzl M.

Carcinogenesis. 2013 Jan;34(1):153-62. doi: 10.1093/carcin/bgs310. Epub 2012 Oct 6.

PMID:
23042300

Supplemental Content

Support Center